Summary
According to APO Research, The global Pharmacogenomics Technology (Theranostics & CDx) market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Pharmacogenomics Technology (Theranostics & CDx) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Pharmacogenomics Technology (Theranostics & CDx) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Pharmacogenomics Technology (Theranostics & CDx) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Pharmacogenomics Technology (Theranostics & CDx) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Pharmacogenomics Technology (Theranostics & CDx) include Illumina, F. Hoffmann-La Roche, Agilent, Abbott, Thermo Fisher Scientific, Qiagen, Guardant Health, MGI Tech and Amoy Diagnostics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Pharmacogenomics Technology (Theranostics & CDx), market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Pharmacogenomics Technology (Theranostics & CDx), also provides the revenue of main regions and countries. Of the upcoming market potential for Pharmacogenomics Technology (Theranostics & CDx), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pharmacogenomics Technology (Theranostics & CDx) revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Pharmacogenomics Technology (Theranostics & CDx) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Pharmacogenomics Technology (Theranostics & CDx) revenue, projected growth trends, production technology, application and end-user industry.
Pharmacogenomics Technology (Theranostics & CDx) segment by Company
Illumina
F. Hoffmann-La Roche
Agilent
Abbott
Thermo Fisher Scientific
Qiagen
Guardant Health
MGI Tech
Amoy Diagnostics
BGI Group
Pharmacogenomics Technology (Theranostics & CDx) segment by Type
Instruments
Reagents and Consumables
Other
Pharmacogenomics Technology (Theranostics & CDx) segment by Application
Tumour
Diabetes
Mental Illness
Cardiovascular Disease
Other
Pharmacogenomics Technology (Theranostics & CDx) segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacogenomics Technology (Theranostics & CDx) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pharmacogenomics Technology (Theranostics & CDx) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacogenomics Technology (Theranostics & CDx).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Pharmacogenomics Technology (Theranostics & CDx) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Pharmacogenomics Technology (Theranostics & CDx) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharmacogenomics Technology (Theranostics & CDx) revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 Pharmacogenomics Technology (Theranostics & CDx) Market by Type
1.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Instruments
1.2.3 Reagents and Consumables
1.2.4 Other
1.3 Pharmacogenomics Technology (Theranostics & CDx) Market by Application
1.3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Tumour
1.3.3 Diabetes
1.3.4 Mental Illness
1.3.5 Cardiovascular Disease
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics
2.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends
2.2 Pharmacogenomics Technology (Theranostics & CDx) Industry Drivers
2.3 Pharmacogenomics Technology (Theranostics & CDx) Industry Opportunities and Challenges
2.4 Pharmacogenomics Technology (Theranostics & CDx) Industry Restraints
3 Global Growth Perspective
3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Perspective (2019-2030)
3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Growth Trends by Region
3.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2019-2024)
3.2.3 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Players
4.1.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Players (2019-2024)
4.1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2019-2024)
4.1.3 Global Pharmacogenomics Technology (Theranostics & CDx) Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Pharmacogenomics Technology (Theranostics & CDx) Key Players Headquarters & Area Served
4.4 Global Pharmacogenomics Technology (Theranostics & CDx) Players, Product Type & Application
4.5 Global Pharmacogenomics Technology (Theranostics & CDx) Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market CR5 and HHI
4.6.2 Global Top 5 and 10 Pharmacogenomics Technology (Theranostics & CDx) Players Market Share by Revenue in 2023
4.6.3 2023 Pharmacogenomics Technology (Theranostics & CDx) Tier 1, Tier 2, and Tier 3
5 Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2030)
5.3 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2019-2030)
6 Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
6.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2030)
6.3 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Illumina
7.1.1 Illumina Comapny Information
7.1.2 Illumina Business Overview
7.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2019-2024)
7.1.4 Illumina Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
7.1.5 Illumina Recent Developments
7.2 F. Hoffmann-La Roche
7.2.1 F. Hoffmann-La Roche Comapny Information
7.2.2 F. Hoffmann-La Roche Business Overview
7.2.3 F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2019-2024)
7.2.4 F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
7.2.5 F. Hoffmann-La Roche Recent Developments
7.3 Agilent
7.3.1 Agilent Comapny Information
7.3.2 Agilent Business Overview
7.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2019-2024)
7.3.4 Agilent Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
7.3.5 Agilent Recent Developments
7.4 Abbott
7.4.1 Abbott Comapny Information
7.4.2 Abbott Business Overview
7.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2019-2024)
7.4.4 Abbott Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
7.4.5 Abbott Recent Developments
7.5 Thermo Fisher Scientific
7.5.1 Thermo Fisher Scientific Comapny Information
7.5.2 Thermo Fisher Scientific Business Overview
7.5.3 Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2019-2024)
7.5.4 Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
7.5.5 Thermo Fisher Scientific Recent Developments
7.6 Qiagen
7.6.1 Qiagen Comapny Information
7.6.2 Qiagen Business Overview
7.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2019-2024)
7.6.4 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
7.6.5 Qiagen Recent Developments
7.7 Guardant Health
7.7.1 Guardant Health Comapny Information
7.7.2 Guardant Health Business Overview
7.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2019-2024)
7.7.4 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
7.7.5 Guardant Health Recent Developments
7.8 MGI Tech
7.8.1 MGI Tech Comapny Information
7.8.2 MGI Tech Business Overview
7.8.3 MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2019-2024)
7.8.4 MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
7.8.5 MGI Tech Recent Developments
7.9 Amoy Diagnostics
7.9.1 Amoy Diagnostics Comapny Information
7.9.2 Amoy Diagnostics Business Overview
7.9.3 Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2019-2024)
7.9.4 Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
7.9.5 Amoy Diagnostics Recent Developments
7.10 BGI Group
7.10.1 BGI Group Comapny Information
7.10.2 BGI Group Business Overview
7.10.3 BGI Group Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (2019-2024)
7.10.4 BGI Group Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
7.10.5 BGI Group Recent Developments
8 North America
8.1 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue (2019-2030)
8.2 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2030)
8.2.1 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2024)
8.2.2 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2025-2030)
8.3 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2019-2030)
8.4 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2030)
8.4.1 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2024)
8.4.2 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2025-2030)
8.5 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2019-2030)
8.6 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country
8.6.1 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019-2024)
8.6.3 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2025-2030)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue (2019-2030)
9.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2030)
9.2.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2024)
9.2.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2025-2030)
9.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2019-2030)
9.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2030)
9.4.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2024)
9.4.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2025-2030)
9.5 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2019-2030)
9.6 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country
9.6.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019-2024)
9.6.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China Pharmacogenomics Technology (Theranostics & CDx) Revenue (2019-2030)
10.2 China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2030)
10.2.1 China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2024)
10.2.2 China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2025-2030)
10.3 China Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2019-2030)
10.4 China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2030)
10.4.1 China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2024)
10.4.2 China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2025-2030)
10.5 China Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue (2019-2030)
11.2 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2030)
11.2.1 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2024)
11.2.2 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2025-2030)
11.3 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2019-2030)
11.4 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2030)
11.4.1 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2024)
11.4.2 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2025-2030)
11.5 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2019-2030)
11.6 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country
11.6.1 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019-2024)
11.6.3 Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue (2019-2030)
12.2 MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2030)
12.2.1 MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2024)
12.2.2 MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2025-2030)
12.3 MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2019-2030)
12.4 MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2030)
12.4.1 MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2024)
12.4.2 MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2025-2030)
12.5 MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2019-2030)
12.6 MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country
12.6.1 MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019-2024)
12.6.3 MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
List of Tables
Table 1. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Instruments Major Manufacturers
Table 2. Reagents and Consumables Major Manufacturers
Table 3. Other Major Manufacturers
Table 4. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 5. Tumour Major Manufacturers
Table 6. Diabetes Major Manufacturers
Table 7. Mental Illness Major Manufacturers
Table 8. Cardiovascular Disease Major Manufacturers
Table 9. Other Major Manufacturers
Table 10. Pharmacogenomics Technology (Theranostics & CDx) Industry Trends
Table 11. Pharmacogenomics Technology (Theranostics & CDx) Industry Drivers
Table 12. Pharmacogenomics Technology (Theranostics & CDx) Industry Opportunities and Challenges
Table 13. Pharmacogenomics Technology (Theranostics & CDx) Industry Restraints
Table 14. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 15. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2019-2024) & (US$ Million)
Table 16. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2019-2024)
Table 17. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2025-2030) & (US$ Million)
Table 18. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2025-2030)
Table 19. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Players (US$ Million) & (2019-2024)
Table 20. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2019-2024)
Table 21. Global Pharmacogenomics Technology (Theranostics & CDx) Key Players Ranking, 2022 VS 2023 VS 2024
Table 22. Global Pharmacogenomics Technology (Theranostics & CDx) Key Players Headquarters & Area Served
Table 23. Global Pharmacogenomics Technology (Theranostics & CDx) Players, Product Type & Application
Table 24. Global Pharmacogenomics Technology (Theranostics & CDx) Players Commercialization Time
Table 25. Global Players Market Concentration Ratio (CR5 and HHI)
Table 26. Global Pharmacogenomics Technology (Theranostics & CDx) by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 27. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 28. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2024) & (US$ Million)
Table 29. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2025-2030) & (US$ Million)
Table 30. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 31. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 32. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 33. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2024) & (US$ Million)
Table 34. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2025-2030) & (US$ Million)
Table 35. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 36. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 37. Illumina Company Information
Table 38. Illumina Business Overview
Table 39. Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 40. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
Table 41. Illumina Recent Development
Table 42. F. Hoffmann-La Roche Company Information
Table 43. F. Hoffmann-La Roche Business Overview
Table 44. F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 45. F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
Table 46. F. Hoffmann-La Roche Recent Development
Table 47. Agilent Company Information
Table 48. Agilent Business Overview
Table 49. Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 50. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
Table 51. Agilent Recent Development
Table 52. Abbott Company Information
Table 53. Abbott Business Overview
Table 54. Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 55. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
Table 56. Abbott Recent Development
Table 57. Thermo Fisher Scientific Company Information
Table 58. Thermo Fisher Scientific Business Overview
Table 59. Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 60. Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
Table 61. Thermo Fisher Scientific Recent Development
Table 62. Qiagen Company Information
Table 63. Qiagen Business Overview
Table 64. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 65. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
Table 66. Qiagen Recent Development
Table 67. Guardant Health Company Information
Table 68. Guardant Health Business Overview
Table 69. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 70. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
Table 71. Guardant Health Recent Development
Table 72. MGI Tech Company Information
Table 73. MGI Tech Business Overview
Table 74. MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 75. MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
Table 76. MGI Tech Recent Development
Table 77. Amoy Diagnostics Company Information
Table 78. Amoy Diagnostics Business Overview
Table 79. Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 80. Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
Table 81. Amoy Diagnostics Recent Development
Table 82. BGI Group Company Information
Table 83. BGI Group Business Overview
Table 84. BGI Group Pharmacogenomics Technology (Theranostics & CDx) Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 85. BGI Group Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
Table 86. BGI Group Recent Development
Table 87. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2024) & (US$ Million)
Table 88. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2024) & (US$ Million)
Table 89. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 90. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019-2024) & (US$ Million)
Table 91. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2025-2030) & (US$ Million)
Table 92. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2024) & (US$ Million)
Table 93. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2024) & (US$ Million)
Table 94. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 95. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019-2024) & (US$ Million)
Table 96. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2025-2030) & (US$ Million)
Table 97. China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2024) & (US$ Million)
Table 98. China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2024) & (US$ Million)
Table 99. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2024) & (US$ Million)
Table 100. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2024) & (US$ Million)
Table 101. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 102. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019-2024) & (US$ Million)
Table 103. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2025-2030) & (US$ Million)
Table 104. MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019-2024) & (US$ Million)
Table 105. MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019-2024) & (US$ Million)
Table 106. MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 107. MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2019-2024) & (US$ Million)
Table 108. MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2025-2030) & (US$ Million)
Table 109. Research Programs/Design for This Report
Table 110. Authors List of This Report
Table 111. Secondary Sources
Table 112. Primary Sources
List of Figures
Figure 1. Pharmacogenomics Technology (Theranostics & CDx) Product Picture
Figure 2. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Share 2019 VS 2023 VS 2030
Figure 4. Instruments Picture
Figure 5. Reagents and Consumables Picture
Figure 6. Other Picture
Figure 7. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 8. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Share 2019 VS 2023 VS 2030
Figure 9. Tumour Picture
Figure 10. Diabetes Picture
Figure 11. Mental Illness Picture
Figure 12. Cardiovascular Disease Picture
Figure 13. Other Picture
Figure 14. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (US$ Million) & (2019-2030)
Figure 15. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region: 2019 VS 2023 VS 2030
Figure 17. Global Pharmacogenomics Technology (Theranostics & CDx) Players Revenue Share Top 10 and Top 5 in 2023
Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 19. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 20. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share 2019 VS 2023 VS 2030
Figure 21. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2019-2030)
Figure 22. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 23. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 24. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2019-2030)
Figure 25. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 26. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2025-2030) & (US$ Million)
Figure 27. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2019-2030)
Figure 28. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2025-2030) & (US$ Million)
Figure 29. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2019-2030)
Figure 30. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Country (2019-2030)
Figure 31. United States Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 32. Canada Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 33. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 34. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2025-2030) & (US$ Million)
Figure 35. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2019-2030)
Figure 36. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2025-2030) & (US$ Million)
Figure 37. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2019-2030)
Figure 38. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Country (2019-2030)
Figure 39. Germany Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. France Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. U.K. Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. Italy Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. Russia Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. Nordic Countries Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 45. China Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 46. China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2025-2030) & (US$ Million)
Figure 47. China Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2019-2030)
Figure 48. China Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2025-2030) & (US$ Million)
Figure 49. China Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2019-2030)
Figure 50. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 51. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2025-2030) & (US$ Million)
Figure 52. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2019-2030)
Figure 53. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2025-2030) & (US$ Million)
Figure 54. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2019-2030)
Figure 55. Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Country (2019-2030)
Figure 56. Japan Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. South Korea Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. India Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. Australia Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. China Taiwan Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 61. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 62. MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 63. MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2025-2030) & (US$ Million)
Figure 64. MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2019-2030)
Figure 65. MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2025-2030) & (US$ Million)
Figure 66. MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2019-2030)
Figure 67. MEALA Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Country (2019-2030)
Figure 68. Mexico Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 69. South Korea Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. Brazil Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Israel Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Argentina Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Colombia Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Turkey Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 76. UAE Pharmacogenomics Technology (Theranostics & CDx) Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 77. Years Considered
Figure 78. Research Process
Figure 79. Key Executives Interviewed
